# ClearPoint Neuro, Inc.: overview CLPT · Nasdaq · CIK 1285550 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/clpt.md) · [Financials](/companies/clpt/financials.md) · [Filings](/companies/clpt/filings.md) · [Insiders](/companies/clpt/insiders.md) Latest reported revenue: [$12.1m](/filings/0001193125-26-436412.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 28, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-436412). ## Last eight quarters | Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [7.8 d](/filings/0001193125-26-111231.md) | [8.5](/filings/0001193125-26-221890.md) | [9.2](/filings/0001193125-26-330842.md) | [8.9](/filings/0001193125-26-436412.md) | [10.4 d](/filings/0001193125-26-111231.md) | [12.1](/filings/0001193125-26-221890.md) | [10.9](/filings/0001193125-26-330842.md) | [12.1](/filings/0001193125-26-436412.md) | | Gross margin | % | [61.3% d](/filings/0001193125-26-111231.md) | [60.5%](/filings/0001193125-26-221890.md) | [60.3%](/filings/0001193125-26-330842.md) | [63.2%](/filings/0001193125-26-436412.md) | [61.5% d](/filings/0001193125-26-111231.md) | [64.0%](/filings/0001193125-26-221890.md) | [61.7%](/filings/0001193125-26-330842.md) | [58.5%](/filings/0001193125-26-436412.md) | | Operating margin | % | [(72.5%) d](/filings/0001193125-26-111231.md) | [(72.6%)](/filings/0001193125-26-221890.md) | [(61.6%)](/filings/0001193125-26-330842.md) | [(59.5%)](/filings/0001193125-26-436412.md) | [(67.7%) d](/filings/0001193125-26-111231.md) | [(69.9%)](/filings/0001193125-26-221890.md) | [(94.2%)](/filings/0001193125-26-330842.md) | [(52.4%)](/filings/0001193125-26-436412.md) | | Net margin | % | [(69.3%) d](/filings/0001193125-26-111231.md) | [(71.0%)](/filings/0001193125-26-436412.md) | [(63.3%)](/filings/0001193125-26-436412.md) | [(66.5%)](/filings/0001193125-26-436412.md) | [(74.8%) d](/filings/0001193125-26-111231.md) | [(78.8%)](/filings/0001193125-26-436412.md) | [(104.2%)](/filings/0001193125-26-436412.md) | [(61.8%)](/filings/0001193125-26-436412.md) | | Diluted EPS | $ per share | not reported | [(0.22)](/filings/0001193125-26-221890.md) | [(0.21)](/filings/0001193125-26-330842.md) | [(0.21)](/filings/0001193125-26-436412.md) | not reported | [(0.32)](/filings/0001193125-26-221890.md) | [(0.38)](/filings/0001193125-26-330842.md) | [(0.24)](/filings/0001193125-26-436412.md) | | Free cash flow | $m | [(1.5) d](/filings/0001193125-26-111231.md) | [(6.4)](/filings/0001193125-26-221890.md) | [(2.6) d](/filings/0001193125-26-330842.md) | [(3.3) d](/filings/0001193125-26-436412.md) | [(12.1) d](/filings/0001193125-26-436412.md) | [(8.6)](/filings/0001193125-26-221890.md) | [(7.2) d](/filings/0001193125-26-330842.md) | [(20.2) d](/filings/0001193125-26-436412.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [16.3](/filings/0001285550-23-000020.md) | [20.6](/filings/0001285550-24-000031.md) | [24.0](/filings/0000950170-25-027934.md) | [31.4](/filings/0001193125-26-111231.md) | [37.0](/filings/0001193125-26-111231.md) | | Gross margin | % | [68.2%](/filings/0001285550-23-000020.md) | [65.8%](/filings/0001285550-24-000031.md) | [56.8%](/filings/0000950170-25-027934.md) | [60.9%](/filings/0001193125-26-111231.md) | [61.4%](/filings/0001193125-26-111231.md) | | Operating margin | % | [(82.1%)](/filings/0001285550-23-000020.md) | [(79.5%)](/filings/0001285550-24-000031.md) | [(93.7%)](/filings/0000950170-25-027934.md) | [(62.9%)](/filings/0001193125-26-111231.md) | [(65.4%)](/filings/0001193125-26-111231.md) | | Net margin | % | [(88.4%)](/filings/0001285550-23-000020.md) | [(80.0%)](/filings/0001285550-24-000031.md) | [(92.2%)](/filings/0000950170-25-027934.md) | [(60.3%)](/filings/0001193125-26-111231.md) | [(69.1%)](/filings/0001193125-26-111231.md) | | Diluted EPS | $ per share | [(0.69)](/filings/0001285550-23-000020.md) | [(0.68)](/filings/0001285550-24-000031.md) | [(0.90)](/filings/0000950170-25-027934.md) | [(0.70)](/filings/0001193125-26-111231.md) | [(0.90)](/filings/0001193125-26-111231.md) | | Free cash flow | $m | [(12.9)](/filings/0001285550-23-000020.md) | [(16.4)](/filings/0001285550-24-000031.md) | [(14.4)](/filings/0000950170-25-027934.md) | [(9.2)](/filings/0001193125-26-111231.md) | [(24.4)](/filings/0001193125-26-436412.md) | - Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/clpt/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $42.5m | 2,379,804 | | Added +297,054 | | [MAK CAPITAL ONE LLC](/funds/1385702.md) | 2026-06-30 | $42.4m | 2,375,861 | | Added +474,372 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $22.0m | 1,232,807 | | Reduced −10,808 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $14.6m | 816,547 | | Added +136,728 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $13.4m | 749,932 | | Added +44,212 | | [Lane Generational LLC](/funds/1901384.md) | 2026-06-30 | $7.9m | 444,831 | | Reduced −42,018 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $7.6m | 428,632 | | Reduced −3,728 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $6.4m | 357,676 | | Added +125,702 | | [BROWN ADVISORY INC](/funds/1345929.md) | 2026-06-30 | $5.8m | 325,906 | | Unchanged | | [COMPASS FINANCIAL MANAGEMENT LLC](/funds/2148724.md) | 2026-06-30 | $5.3m | 295,680 | | Not compared | ## Recent filings [All 1,271 filings](/companies/clpt/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-28 | 17:25 ET | [10-Q](/filings/0001193125-26-436412.md) | Quarterly report, period 2026-09-30 | 0001193125-26-436412 | | 2026-10-28 | 16:05 ET | [8-K](/filings/0001193125-26-436125.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-436125 | | 2026-08-03 | 17:17 ET | [10-Q](/filings/0001193125-26-330842.md) | Quarterly report, period 2026-06-30 | 0001193125-26-330842 | | 2026-08-03 | 16:05 ET | [8-K](/filings/0001193125-26-330541.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-330541 | | 2026-05-21 | 16:30 ET | [8-K](/filings/0001193125-26-234571.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-234571 | | 2026-05-13 | 17:00 ET | [10-Q](/filings/0001193125-26-221890.md) | Quarterly report, period 2026-03-31 | 0001193125-26-221890 | | 2026-05-13 | 16:05 ET | [8-K](/filings/0001193125-26-221596.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-221596 | | 2026-04-10 | 16:30 ET | [DEF 14A](/filings/0001193125-26-151345.md) | Proxy statement, period 2026-04-10 | 0001193125-26-151345 | | 2026-03-17 | 17:21 ET | [10-K](/filings/0001193125-26-111231.md) | Annual report, period 2025-12-31 | 0001193125-26-111231 | | 2026-03-17 | 16:08 ET | [8-K](/filings/0001193125-26-110780.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-110780 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-111231.md), filed Mar 17, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, has been scored from the reported figures. [See the target](/leagues/2026q3/targets/c406875b-838a-47e7-a7e8-a7bd737e6f9e) ## About the filer - CIK: 1285550 - Tickers: CLPT - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 05:15 ET. No prices; not investment advice.